Paper Details

  1. Home
  2. Paper Details

The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation.

Author: , AkarcaU S, CakalogluY, FlinkH J, GerkenG, HansenB E, JanssenH L A, SchalmS W, SenturkH, SimonC, SoT M K, VerheyE, ZeuzemS, de ManR A, van ZonneveldM

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Pegylated interferon alfa-2b is a safe treatment for chronic hepatitis B with compensated liver disease. The most frequent side effects were flu-like symptoms, headache, and fatigue. Dose reduction or early treatment discontinuation was more likely in patients with cirrhosis or low neutrophil count at baseline.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Treatment with interferon-alpha has been shown to be effective in one-third of hepatitis B e antigen-positive chronic hepatitis B patients, but is clinically associated with relevant adverse events. AIM: To investigate the safety of pegylated interferon alpha-2b in 300 hepatitis B e ant...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1365-2036.2005.02453.x

データ提供：米国国立医学図書館（NLM）

Pegylated Interferon Alpha-2b: Safety in Hepatitis B Treatment

This research takes us into the world of infectious diseases, focusing on the treatment of chronic hepatitis B, a viral infection that can lead to serious liver damage. This study examines the safety of pegylated interferon alpha-2b, a medication used to treat chronic hepatitis B, in a group of patients with compensated liver disease.

The researchers found that pegylated interferon alpha-2b was generally safe and well-tolerated in these patients. The most common side effects were flu-like symptoms, headache, and fatigue. The study also identified pre-existing cirrhosis and low neutrophil count at baseline as independent predictors of dose reduction or early treatment discontinuation.

Navigating the Risks and Benefits of Hepatitis B Treatment

This study provides valuable insights into the safety and efficacy of pegylated interferon alpha-2b in treating chronic hepatitis B. It highlights the importance of careful monitoring for potential side effects and the need to adjust treatment strategies based on individual patient characteristics. It’s like a camel navigating a desert landscape, aware of the potential dangers of heat, dehydration, and sandstorms.

Making Informed Decisions About Hepatitis B Treatment

This research underscores the importance of open communication between patients and healthcare providers to make informed decisions about treatment options. Patients with chronic hepatitis B should discuss the potential benefits and risks of pegylated interferon alpha-2b with their doctor to determine the most appropriate course of action.

Dr. Camel’s Conclusion

This study provides important information regarding the safety and efficacy of pegylated interferon alpha-2b in treating chronic hepatitis B. It highlights the importance of careful monitoring for potential side effects and the need to adjust treatment strategies based on individual patient characteristics. This research is a reminder that we must strive for a balanced approach to treatment, considering both the potential benefits and risks to ensure optimal outcomes for patients.
Date :
  1. Date Completed 2005-08-01
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

15854180

DOI: Digital Object Identifier

10.1111/j.1365-2036.2005.02453.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.